Peanut Allergy Treatment in 2026: OIT, Xolair, and What's Next

For most of my life, the only “treatment” for a peanut allergy was strict avoidance and an epinephrine auto-injector. That’s changing. There’s now a small but growing toolkit of therapies that aim to reduce the danger of an accidental exposure — and 2026 brought some big shifts. Here’s a plain-English guide to where peanut allergy treatment stands today.

First, the honest framing: there’s no cure

No current treatment cures a peanut allergy. What today’s therapies aim to do is raise your threshold — so that an accidental bite is less likely to cause a severe reaction. They reduce risk; they don’t remove the allergy. Strict avoidance and carrying epinephrine remain the foundation no matter what.

Oral immunotherapy (OIT)

Oral immunotherapy works by giving tiny, gradually increasing amounts of peanut protein under medical supervision, training the immune system to tolerate more before reacting. It’s done only with an allergist — never at home on your own — because doses can themselves cause reactions.

The big 2026 news: Palforzia, the first and only FDA-approved standardized peanut OIT (for children ages 1–17), is being discontinued on July 31, 2026. Importantly, this is a business decision — not a safety, quality, or effectiveness problem. Families currently on Palforzia should talk to their allergist about transitioning.

With Palforzia winding down, many allergists offer office-based OIT using carefully measured peanut products and established protocols. It’s a well-established approach, just not a branded, pre-packaged one.

Xolair (omalizumab)

Xolair is the first biologic medication approved as a food allergy therapy. It’s an injection given every 2–4 weeks for adults and children ages 1 and up, and it works by blocking IgE — the antibody behind allergic reactions. Rather than building tolerance to a specific food, it raises the bar for reactions across allergens, which is promising for people with multiple food allergies.

What’s on the horizon

The pipeline is active:

Ozureprubart — an anti-IgE therapy that may need dosing only about every 12 weeks (GSK acquired its developer in early 2026).
Sublingual immunotherapy (SLIT) — peanut protein delivered under the tongue, which has performed well in several studies and may offer a gentler side-effect profile than OIT.

How to think about your options

If you or your child is considering treatment, a few principles help:

Talk to a board-certified allergist who offers these therapies — this is not a do-it-yourself project.
Be clear on the goal: most treatments aim for protection from accidental exposure, not freedom to eat peanuts.
Weigh the commitment: OIT requires frequent visits and daily dosing; biologics require ongoing injections.
Keep your epinephrine. Every current therapy is an addition to — not a replacement for — avoidance and emergency preparedness.

The bottom line

Peanut allergy treatment in 2026 is more hopeful than it’s ever been, even with Palforzia ending. Between office-based OIT, Xolair, and a busy research pipeline, there are real options worth discussing with your allergist. For the basics on recognizing reactions, see peanut allergy symptoms in adults.

Sources

Not medical adviceThis is an educational overview of publicly reported treatments, not a recommendation. Treatment decisions must be made with a qualified allergist.

#treatment #immunotherapy #Palforzia #Xolair #research